Search results

• Early
  onset Alzheimer's disease. == Early onset Alzheimer's disease ==
  2 KB (277 words) - 04:04, 4 February 2024
• Early-onset Alzheimer's disease
  '''Early-onset Alzheimer's disease''' ...s a form of [[Alzheimer's disease]] that affects individuals under the age of 65.
  2 KB (272 words) - 22:13, 7 February 2024
• Alzheimer's Association
  == Alzheimer's Association == ...the leading voice for Alzheimer's disease advocacy, fighting for critical Alzheimer's research, prevention, and care initiatives at the state and federal level.
  2 KB (206 words) - 06:16, 11 February 2024
• Aducanumab-avwa
  ...s a monoclonal antibody medication used for the treatment of [[Alzheimer's disease]]. ...designation indicating the specific formulation and manufacturing process of the drug.
  1 KB (192 words) - 22:23, 7 February 2024
• Solanezumab
  ...) is a [[monoclonal antibody]] designed for the treatment of [[Alzheimer's disease]]. It is developed by [[Eli Lilly and Company]], a global pharmaceutical co ...in word "solane", meaning "alone", and "zumab", a suffix used in the names of humanized monoclonal antibodies.
  1 KB (171 words) - 00:15, 7 February 2024
• Alzheimer's Disease
  == Alzheimer's Disease == ...vior. It is the most common cause of [[dementia]], a general term for loss of memory and other cognitive abilities serious enough to interfere with daily
  2 KB (274 words) - 17:14, 10 February 2024
• Aducanumab
  ...onoclonal antibody medication developed for the treatment of [[Alzheimer's disease]]. ...du-", meaning towards, and "canumab", a suffix commonly used in the naming of monoclonal antibodies.
  1 KB (199 words) - 23:10, 5 February 2024
• Gantenerumab
  ...l antibody]] that is being investigated for the treatment of [[Alzheimer's disease]]. === Mechanism of Action ===
  1 KB (148 words) - 23:52, 6 February 2024
• Alzheimers
  == Alzheimer's Disease == ...vior. It is the most common cause of [[dementia]], a general term for loss of memory and other cognitive abilities serious enough to interfere with daily
  2 KB (294 words) - 22:50, 5 February 2024
• Intepirdine
  ...e) is a drug that was under development for the treatment of [[Alzheimer's disease]] and other [[neurodegenerative diseases]]. ...e". This refers to the drug's intended function of slowing the progression of cognitive decline in neurodegenerative diseases.
  1 KB (158 words) - 17:41, 6 February 2024
• Cerlapirdine
  ...ation: /sɛrˈlæpɪrdiːn/) is a [[pharmaceutical drug]] used in the treatment of [[neurodegenerative diseases]]. ...urodegenerative diseases such as [[Alzheimer's disease]] and [[Parkinson's disease]]. It functions by enhancing the cholinergic function, which is often impai
  932 bytes (103 words) - 23:53, 6 February 2024
• Rislenemdaz
  ...rodegenerative diseases, such as [[Alzheimer's disease]] and [[Parkinson's disease]]. ...lp to reduce the excitotoxicity that is thought to contribute to the death of neurons in neurodegenerative diseases.
  1 KB (158 words) - 17:30, 6 February 2024
• ADRD
  == Alzheimer's Disease and Related Dementias (ADRD) == ...ral dementia]]. These conditions are characterized by the progressive loss of mental functions such as memory, attention, and the ability to perform simp
  2 KB (277 words) - 16:18, 3 February 2024
• Tarenflurbil
  ...t was investigated for its potential use in the treatment of [[Alzheimer's disease]]. The name "Tarenflurbil" is a combination of parts of the chemical name for the drug, which is 2-[[phenylmethyl]]amino]-5-[[trifl
  2 KB (209 words) - 02:59, 7 February 2024
• Rivastigmine tartrate
  ...d primarily for the treatment of [[Alzheimer's disease]] and [[Parkinson's disease]]. ...imetic]] or [[cholinergic]] agents. The "tartrate" refers to the salt form of the drug, which is combined with tartaric acid to improve its stability and
  2 KB (210 words) - 06:37, 11 February 2024
• J147
  ...ntal drug with potential therapeutic use in the treatment of [[Alzheimer's disease]] and other age-related diseases. The name "J147" is derived from the initials of the Salk Institute's Cellular Neurobiology Laboratory's director, Juan Carl
  1 KB (187 words) - 03:57, 4 February 2024
• Alzheimer's dementia
  == Alzheimer's dementia == ...is the most common cause of [[dementia]], accounting for 60 to 80 percent of dementia cases.
  2 KB (246 words) - 03:47, 11 February 2024
• Donanemab
  ...) is a [[monoclonal antibody]] designed for the treatment of [[Alzheimer's disease]]. It is developed by [[Eli Lilly and Company]], a multinational pharmaceut === Mechanism of Action ===
  1 KB (175 words) - 16:33, 5 February 2024
• Bapineuzumab
  ...tibody that was under development as a potential treatment for Alzheimer's disease. ...is targeted by the drug. "Ineuzumab" is a common suffix used in the names of monoclonal antibodies.
  1 KB (199 words) - 00:07, 7 February 2024
• Memantine
  ...ɛˈmæntiːn/) is a medication used to treat moderate-to-severe [[Alzheimer's disease]]. It is classified under the drug class known as [[NMDA receptor antagonis ...s memory, and the suffix "-antine" which is often used in the nomenclature of pharmaceutical substances.
  2 KB (205 words) - 19:43, 5 February 2024

View (previous 20 | next 20) (20 | 50 | 100 | 250 | 500)